Oncotarget
Correspondence to - Mary J. Janatpour, email: mjanatpour@dynavax.com
Keywords: TLR9, SD-101, cyclophosphamide, immune therapy, innate immunity
Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC